FDA Approves Valacyclovir

April 1, 2003

San Diego - The U.S. Food and Drug Administration approved a supplemental new drug application for Valtrex (valacyclovir HCl) caplets (Glaxo SmithKline) for the suppression of recurrent genital herpes in HIV-infected individuals. Once daily dosage has been shown to reduce the transmission of symptomatic genital herpes in healthy heterosexual monogamous couples by more than three-quarters, according to Lawrence Corey, M.D.

Related Content:

News